Tevogen Bio Holdings, Inc.
TVGNTevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies for infectious diseases, cancers, and other disorders.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies for infectious diseases, cancers, and other disorders. The company utilizes its proprietary ExacTcell technology to harness naturally occurring CD8+ cytotoxic T lymphocytes (CTLs) without genetic engineering. Its core value proposition is the creation of cost-effective, allogeneic T cell products that can be administered in outpatient settings to address large, underserved patient populations.
A clinical-stage innovator seeking to mainstream cell therapy through a proprietary, non-genetically modified allogeneic platform designed for scalability and lower cost compared to traditional CAR-T therapies.
Questions, answered.
- What is Tevogen Bio Holdings, Inc.'s market cap?
- Tevogen Bio Holdings, Inc. (TVGN) has a market capitalization of $23.5M and trades on NASDAQ.
- Who are Tevogen Bio Holdings, Inc.'s competitors?
- Tevogen Bio Holdings, Inc.'s key competitors include Atara Biotherapeutics, Pfizer, Gilead Sciences, and others. These companies compete in similar markets and product categories.
- Who does Tevogen Bio Holdings, Inc. partner with?
- Tevogen Bio Holdings, Inc.'s notable partners include Microsoft, Thomas Jefferson University, Adaptive Biotechnologies.
- What subsidiaries does Tevogen Bio Holdings, Inc. have?
- Tevogen Bio Holdings, Inc.'s subsidiaries include Tevogen Bio Inc..
- Where is Tevogen Bio Holdings, Inc. headquartered?
- Tevogen Bio Holdings, Inc. is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 2024.